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ABSTRACT
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive neoplastic disorder 
in which chemotherapy resistance and refractory relapses occur, with a poorer 
prognostic outcome.
Constitutively active PI3K/Akt/mTOR pathway is a common feature of T-ALL 
upregulating cell proliferation, survival and drug resistance. This pathway is currently 
under clinical trials with small molecules inhibitors (SMI).
To verify whether a multi-inhibition treatment against Akt protein could enhance 
the efficacy of individual drug administration and overcome drug resistance as well 
as to obtain a decrease in single drug concentration, we tested on T-ALL cell lines 
the effects of combined treatments with three Akt inhibitors with different mode of 
action, GSK690693, MK-2206 and Perifosine.
In cells with hyperactivated Akt, combined administration of the drugs displayed 
a significant synergistic and cytotoxic effect and affected PI3K/Akt/mTOR pathway 
at much lower concentration than single drug use. Highest synergistic effect for 
full inhibition of Akt was also related to the timing of every drug administration. 
Furthermore the triple treatment had greater efficacy in inducing cell cycle arrest in 
G0/G1 phase and both apoptosis and autophagy.
Targeting Akt as a key protein of PI3K/Akt/mTOR pathway with multiple drugs 
might represent a new and promising pharmacological strategy for treatment of T-ALL 
patients.
INTRODUCTION
T-ALL is an aggressive and heterogeneous blood 
malignancy disease deriving from T-cell progenitors in 
the thymus, with multiple, prognostically relevant genetic 
aberrations [1] and is characterized by the over-production 
of immature white blood cells [2].
T-ALL accounts for 10–15% of pediatric and 25% of 
adult ALL cases [3]. With the current intensified multi-agent 
chemotherapy protocols, the 5-year event-free survival 
(EFS) of children with T-ALL has reached 70–75%, 
whereas the EFS is 30–40% for adults below 60 years of 
age, and 10% above this age [4]. However, these therapies 
are highly toxic and moreover, relapsed patients often 
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develop resistance to chemotherapy and have an extremely 
poor prognosis [5]. Heterogeneity within T-cell leukemia 
can cause avoidance of inhibited nodes and selection of 
subpopulations of inhibitor-resistant cancer cells [6].
Constitutively active PI3K/Akt/mTOR signaling 
is observed in many types of solid and blood tumors, 
including T-cell acute lymphoblastic leukemia (T-ALL), 
where it portends a poorer prognosis and negatively 
influences response to therapeutic treatments [7].
The phosphoinositide 3-kinase (PI3K)/Akt/
mammalian target of rapamycin (mTOR) signal 
transduction cascade controls a wide range of 
physiological cell processes, including proliferation, 
survival, differentiation, metabolism, autophagy, 
angiogenesis, exocytosis, and motility [8]. Activation of 
PI3K recruits cellular protein kinases that in turn activate 
downstream kinases, including the serine/threonine kinase 
Akt. Phosphorylation of Akt activates several substrates, 
including the mTOR complex 1 (mTORC1) and induces 
subsequent phosphorylation of downstream targets such 
as S6K. The activation of mTORC1 results in increased 
translation and protein synthesis [9]. A second complex 
comprising mTOR, known as mTORC2, more recently 
described, appears to act as a feedback loop via Akt 
phosphorylation on Ser 473 [10].
The PI3K/Akt/mTOR network is involved in 
T-ALL survival and drug-resistance and could be targeted 
by small molecules inhibitors (SMI) [11]. The PI3K/
Akt/mTOR inhibitors are currently being developed for 
clinical use either as single agents or in combination with 
conventional chemotherapy for T-ALL patient treatment 
[12].
There is a growing interest in multi-component 
chemotherapy: the combined delivery of multiple drugs 
is an attempt to overcome drug resistances and to improve 
clinical outcome.
Therefore we sought to determine whether the 
combination of drugs with the same target of action, i.e. 
Akt, will result in a more significant biological effect, as 
an antiproliferative therapy in order to overcome the risk 
of cell growth escape phenomena.
To this aim we employed three drugs directed against 
Akt but with a totally different mode of action. GSK690693 
is a small molecule ATP-competitive inhibitor of the pro-
survival kinase Akt, is a pan-Akt kinase inhibitor, has been 
preclinically tested in osteosarcoma and ALL xenografts and 
is now in phase I of clinical trials in sarcomas, neuroblastoma, 
non-glioblastoma brain tumors and lymphoma [13, 14].
MK-2206 is a novel, orally active, potent and 
selective allosteric Akt inhibitor, that inhibits the activities 
of all three human Akt (recombinant full length) isoforms, 
Akt1, 2, and 3 with 50% inhibitory concentration (IC50) 
values of 8, 12, and 65 nM, respectively and which 
is in phase II of clinical trials and has been tested on 
acute myelogenous leukemia [15] and on solid tumors, 
including malignant glioma, melanoma and squamous cell 
carcinoma [16, 17].
Perifosine, is an orally available alkylphospholipid, 
Akt inhibitor, that blocks the recruitment of the pleckstrin 
homology (PH) domain of Akt kinase, to prevent its 
membrane localization and subsequent activation [18, 
19]. It is currently in phase III clinical development for 
treatment of colorectal cancer (CRC, in combination 
with capecitabine) and of multiple myeloma (MM, in 
combination with bortezomib and dexamethasone) [20], 
of chronic lymphocytic leukemia [21] and relapsed or 
refractory acute leukemia (AML or ALL) [22].
Here, we documented that multiple inhibition of Akt 
protein was cytotoxic against T-ALL cells over-expressing 
Ser 473 p-Akt and had synergistic effects, with more potent 
efficacy than single or double compound administration 
at the same concentration. Treatment of T-ALL cells with 
the combination of three drugs caused a potent cell cycle 
arrest in G0/G1 phase, apoptosis and autophagy. Moreover, 
6 h of Perifosine pre-treatment followed by the combined 
administration of MK-2206 and GSK690693, was necessary 
for the complete switch off of the activated protein.
Our findings suggested that multiple Akt targeting 
by drugs with different mechanism of action could 
represent a new promising treatment for T-cell acute 
lymphoblastic leukemia patients with PI3K/Akt/mTOR 
pathway hyperactivation.
RESULTS
PI3K/Akt/mTOR pathway activation status in 
T-ALL cell lines
By Western blot analysis, we first evaluated the 
phosphorylation status of key proteins of the PI3K/Akt/
mTOR pathway in a panel of T-ALL cell lines (JURKAT, 
MOLT-4, CEM-S, CEM-R, PEER and BE-13). PEER and 
BE-13 cells are characterized by the NUP214-ABL1 fusion 
gene mutation, that is the most frequent and highly specific 
ABL1 fusion protein for T-lineage acute lymphoblastic 
leukemia, that transforms T-cells and is a constitutively 
active tyrosine kinase with oncogenic potential [23].
Whereas PEER and BE-13 cells did not displayed 
phosphorylated Akt, the other four cell lines displayed 
an hyperphosphorylated form, which is indicative of 
constitutive activation of PI3K signaling pathway (Fig. 1).
Moreover, we confirmed as previously reported 
[24, 25] the absence of PTEN protein expression in most 
T-ALL cell lines analyzed, except for PEER and BE-13.
Accordingly to the above observations, Ser 2448 and 
Ser 2481 p-mTOR (readout of mTORC1 and mTORC2 
activity) were hyperphosphorylated in NUP214-ABL1 
negative cells.
In PEER and BE-13 cell lines, PTEN was 
phosphorylated at Ser 380, a marker of PTEN post-
translational inactivation and consequent PI3K pathway 
activation [26]. However, despite this observation neither 
Akt nor mTOR appeared hyperphosphorylated.
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Multiple Akt targeting had higher cytotoxic 
effect and synergized only in Ser 473 p-Akt 
expressing cells
We examined by MTT assay the IC50 values of 
each drug on the six T-ALL cell lines. After 24 h of 
treatment, cell lines displayed different sensitivity to the 
single drugs. GSK690693 ranged from 0.31 or 0.21 μM, 
in MOLT-4 and JURKAT, to 7 or 5 μM in CEM-R and 
-S, respectively. MK-2206 IC50 ranged from 1.7 to 6.9 
μM. Perifosine required higher concentration to obtain 
IC50 and ranged between 9.35 and 14.65 μM (Fig. 2A) 
and this phenomenon is well known and has already been 
described [27, 28]. In both PEER and BE-13 the IC50 
values of all the drugs was higher than 15 μM (Fig. 2A).
We next studied if the simultaneous administration 
of GSK690693, MK-2206 and Perifosine could lead to 
a similar cytotoxic effect on the T-ALL cell lines with 
a significant decrease of the concentration of every 
single drug due to the synergy of the three compound 
combination.
Therefore we treated cells with drugs administered 
together for 24 h, using the IC50 value as the highest one 
and decreasing progressively up to 1/20 of the IC50 value. 
MTT assays were then performed.
As shown in Fig. 2B, all the four more responsive 
cell lines showed the synergistic cytotoxicity of the 
triple drug combination, very significant in MOLT-4 and 
JURKAT cells. We calculated the cell index value (CI) 
with Calcusyn Software, to quantify the combined effects 
of the drugs, such as synergism or interference. We did 
not maintain a constant ratio since it was necessary to 
fine tune each drug concentration to better understand the 
synergistic or interfering effect and to avoid a too high 
cytotoxicity depending on a single drug administered 
at a fixed constant ratio. The data analysis (not shown) 
indicated strong synergisms in all cell lines, even more 
evident in MOLT-4 cells, with the best CI value of 
0.101 corresponding to the combination of 0.05 μM 
GSK690693, 0.2 μM MK-2206 and 2 μM Perifosine.
Triple Akt hit increases the inhibition of the 
PI3K/Akt/mTOR signaling pathway
To verify if the multiple and simultaneous in vitro 
treatment with MK-2206, GSK690693 and Perifosine 
could lead to a modulation of PI3K/Akt/mTOR pathway, 
we checked the phosphorylation status of key components 
of this signaling cascade in our panel of more responsive 
cell lines. In particular we analyzed p-Akt, its downstream 
target, GSK3 α/β, and the ribosomal protein S6 kinase, 
readout of mTORC1 activity, after 30 min of drugs 
exposure.
GSK690693 and Perifosine were used at 1/2 of 
the IC50 concentration, whereas MK-2206 was used at 
1/5 of IC50, since half of MK-2206 IC50 concentration 
Figure 1: Expression and phosphorylation status of Akt, PTEN and mTOR in T- ALL cell lines. Western blot analysis of 
T-ALL cell lines to detect the expression and phosphorylation levels of Akt, PTEN and mTOR. Twenty-five μg of protein was blotted to 
each lane. Antibody to β-actin served as a loading control.
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Figure 2: Cytotoxicity of Perifosine, MK-2206 and GSK690693 in T-ALL cell lines. A MOLT-4, JURKAT, CEM-R, CEM-S, 
PEER and BE-13 cell lines were treated for 24 h with increasing concentrations of the drugs, ranging from 0.1 to 20 μM, to determine 
the IC50 value. Results are the mean of three different experiments. SD was less than 10%. B MTT assay of T-ALL cell lines treated with 
Perifosine, MK-2206 and GSK690693, either alone and in triple combination for 24 h. Concentration of each drug is reported under the 
graph. One representative experiment of three is shown.
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was enough to completely abolish the Ser 473 Akt 
phosphorylation already at 30 minutes.
Akt phosphorylation was affected in different 
ways by single drug administration: in all cell lines 
MK-2206 very significantly reduced p-Akt, Perifosine 
only slightly reduced it and GSK690693 on the contrary 
increased the protein phosphorylation. The latter one is 
an already described phenomenon [29]. This increase of 
Akt phosphorylation diminished the observable effect of 
double or triple compound combination, since p-Akt was 
not significantly reduced, unless when using MK-2206 in 
double exposure (Fig. 3A).
On the contrary, even after such a short time 
of treatment, in all of the four cell lines it was very 
evident the efficacy of the multiple hit on Akt. The triple 
administration of the drugs completely abolished the 
phosphorylation on the downstream targets, Ser 21/9 
p-GSK3 α/β and Ser 235/236 p-S6, with a much superior 
efficacy of the triple exposure when compared with the 
single or with the different double combinations (Fig. 3A). 
The total amount of the proteins was unchanged in all the 
treatments (Fig. 3A).
Pre-treatment with Perifosine enhance 
synergistic effect
Given that the GSK690693 drug alone led to Ser 
473 p-Akt increase, whereas MK-2206 alone almost 
turn off the signal, we sought to explore if we can find 
a compound combination capable of synergistically 
dephosphorylate Akt.
We first tested if there is any concentration capable 
to modulate Akt phosphorylation in JURKAT and MOLT-
4 cells. Therefore GSK690693 was administered at 1/2 
of the IC50 value (0.1 μM for JURKAT and 0.15 μM for 
MOLT-4 cells) and MK-2206 was contemporary given 
at increasing concentrations (0.3–0.5–1 μM). After 30 
minutes of exposure, Western blot was performed. The 
best drug combination to observe p-Akt modulation 
resulted to be 1 μM MK-2206 for JURKAT and 0.5 μM 
for MOLT-4 cells (Fig. 3B).
We then analyzed by Western blot the 
phosphorylation levels of Akt after treatment with 7 μM 
Perifosine at different time points. In both cell lines the 
drug affected in a time-dependent manner the Ser 473 Akt 
phosphorylation (Fig. 3C).
Finally, we merged the two previous assays pre-
treating cells for 6 h with Perifosine before a 30 min 
administration of GSK690693 and MK-2206.
As shown in (Fig. 3D), in 6 h Perifosine pre-treated 
cells, the administration of GSK690693 reduced Ser 473 
p-Akt hyperphosphorylation. The combination of all three 
drugs allowed to obtain a full Akt dephosphorylation 
in both MOLT-4 and JURKAT cells, thus showing 
that full Akt inhibition with low drug doses is not only 
concentration but also time and drug sequence dependent.
The triple Akt inhibition induces cell cycle arrest 
and causes autophagy and pro-apoptotic effects 
in T-ALL cells
The significant in vitro antitumor activity of the 
triple anti Akt SMI drug combination on T-ALL cells 
led us to investigate the mechanisms of its antileukemic 
efficacy. To assess the effects of the combined treatment 
on the PI3K pathway, we analyzed the effect of triple 
treatment on cell cycle progression, given the importance 
of the PI3K/Akt/mTOR signaling pathway in the 
regulation of cell proliferation [12].
Flow cytometric analysis of PI-stained samples in 
JURKAT and CEM-S cells was performed. Cells were 
treated with single and triple administration of drugs 
for 24 h. The multiple anti Akt treatment increased the 
percentage of cells in G0/G1 phase of cell cycle, with a 
parallel decrease of both S and G2/M phases (Fig. 4).
It has been reported that Akt targeted drugs induce 
autophagy in human glioma and T-ALL cells [30, 31].
Therefore, we investigated whether the triple 
treatment enhanced autophagy in our T-ALL cell panel. 
The exposure of cells to 24 h of the combined treatment 
increased the amount of lipidated (14-kDa form) LC3A/B 
isoform, a well-established autophagy marker, detected 
by western blot in MOLT-4, JURKAT and CEM-S cells 
(Fig. 5A).
Interestingly it has been previously reported 
that inhibiting autophagy with Chloroquine sensitizes 
non small cell lung cancer cells (NSCLC) to combined 
treatment with Akt inhibitors [32].
We then inhibited autophagy using Bafilomycin A1 
or Chloroquine and measured cell viability after 24 h of 
treatment by MTT assay. Bafilomycin A1 or Chloroquine, 
when used alone, did not significantly affect cell viability. 
However when each drug was combined with triple 
Akt inhibition, it was possible to detect a significantly 
increased cytotoxicity in CEM-S and MOLT-4 cells 
(Fig. 5B). These findings suggest that autophagy could 
protect T-ALL cells by the cytotoxic effects of the Akt 
inhibitors.
We next verified the induction of cleaved PARP, 
a well established apoptotic marker [33], in JURKAT, 
MOLT-4 and CEM-S cell lines by western blotting after 
24 h of treatment. The apoptotic effect of the single drug 
administration was visible in each cell lines compared to 
the control, but was even more evident in MOLT-4 treated 
with MK-2206 and CEM-S treated with GSK690693. 
Interestingly, the triple administration of the drugs displayed 
a higher cleaved PARP in all the three cell lines (Fig. 6A). 
To further strengthen this observation we also analyzed 
caspase-3, which plays an essential role during apoptotic 
cell death [34]: also with this protein the triple exposure to 
drugs induced an increased caspase-3 cleavage (Fig. 6A). 
The percentages of apoptotic cells was examined by flow 
cytometry after staining with annexin-V-FITC and PI. 
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Figure 3: Multiple Akt inhibition affects PI3K/Akt/mTOR pathway and the Akt inhibition is time-dependent.  
A Western blot analysis of Akt drug sensitive T-ALL cell lines for total and phosphorylated form of Akt and of its downstream substrate GSK3 α/β 
and of mTOR downstream target S6. Samples were treated for 30 minutes with GSK690693, MK-2206 and Perifosine, alone or in double or triple 
combinations. B Akt protein inhibition as detected by its phosphorylation status. MOLT-4 and JURKAT cells were treated for 30 minutes with a 
combination of a fixed concentration of GSK690693 and three different concentrations of MK-2206. C Akt phosphorylation levels in cells treated 
with 7 μM Perifosine at different time points. D p-Akt status in MOLT-4 and JURKAT cells pre-treated for 6 h with 7 μM Perifosine followed by 
GSK690693 and MK-2206 administered for 30 minutes. Twenty-five μg of protein was blotted to each lane. β-actin served as a loading control. 
For all panel one representative experiment of three is shown as well as cell lines are representative also of the others if not shown.
D
C
B
A
Oncotarget6603www.impactjournals.com/oncotarget
Flow cytometric analysis confirmed that multiple treatment 
induced a greater, statistically significant, increase in 
apoptosis compared to single drugs (Fig. 6B). In addition 
we studied if Z-VAD-fmk, a pan caspase inhibitor [35] 
would affect the apoptotic process, as detected by annexin 
V staining: cell death was sensitive to the administration of 
50 μM Z-VAD-fmk, that inhibited apoptosis in triple drug 
exposed cells.
The multiple treatment has the capability to 
inhibit ERK pathway
We finally then focused our attention on the MEK/
ERK signaling pathway, which plays an important role in 
cell proliferation and growth [36] and potentially mediates 
resistance to drug-induced growth inhibition [37].
For this reason, we examined the p-ERK 1/2 
phosphorylation status in JURKAT, MOLT-4 and CEM-S 
cells, after 24 h of treatment with the three drugs.
Interestingly, the multiple treatment was capable to 
downregulate the phosphorylation state of Tyr 202/204 
p-ERK 1/2 with a superior efficacy than single drugs, whereas 
the amount of total protein remains unchanged (Fig. 7).
DISCUSSION
PI3K/Akt/mTOR signaling upregulation is very 
common in T-ALL, being detectable in 70–85% of the 
patients [38], and portends a poorer prognosis [39]. 
Although the survival of younger patients with acute 
leukemia has improved in the early 21st century, mutations 
event can occur at any stage of the disease and negatively 
influences the response to therapeutic treatments because 
lead to resistance to therapy.
A major challenge remains the lifelong morbidity 
suffered by patients treated with current chemotherapy 
regimens. For long-term survivors, acute and lasting 
toxicities remain important issues underlining the critical 
need of more effective and selective personalized and 
targeted therapies, and treatment strategies.
A large variety of inhibitors have been widely used 
both in vitro and in vivo in preclinical settings of acute 
Figure 4: Multiple Akt inhibition induces cell cycle arrest. Flow cytometric analysis of PI-stained samples was performed 
on JURKAT and CEM-S cells after 24 h of treatment with Perifosine, GSK690693 and MK-2206 administered both alone or in triple 
combination, always used at the IC50 value. In the table are reported the values of every cell cycle phase obtained in all treatments, 
with the addition of MOLT-4 cells. Asterisks indicate statistically significant differences with respect to untreated cells (*p < 0.05). One 
representative experiment of three is shown as well as cell lines are representative also of the others not shown.
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leukemias, where they blocked cell proliferation and 
induced, sometimes, apoptosis and/or autophagy [40–43]. 
Several studies have highlighted that both PI3K and mTOR 
modulators could synergize with a wide range of drugs that 
are currently in use for treating acute leukemias, including 
chemotherapeutic drugs [44, 45]. Drugs dual targeting 
PI3K/Akt/mTOR pathway at various points of the signaling 
cascade are under evaluation in preclinical models and 
clinical trials, but the observation that not even the combined 
inhibition of Akt and mTOR is enough to completely turn off 
the pathway during chronic treatment is very intriguing [46].
Despite several chemotherapy combinations were 
tested in vitro and are in clinical trials for the treatment 
of acute lymphoblastic leukemia, a new and promising 
innovative idea, for the individualization of the therapies, 
could be represented by hitting the same target with 
multiple specific drugs with different mechanisms of action.
In this study, we demonstrated the efficacy of 
multi-inhibition of the same target, i.e. the Akt protein 
as a pivotal molecule of the PI3K/Akt/mTOR signaling 
pathway with three drugs with a totally different 
mechanism of action.
The triple administration of GSK690693, MK-
2206 and Perifosine in cells with Ser 473 p-Akt 
hyperphosphorylation was cytotoxic and synergic at lower 
doses when compared with the IC50 values. We showed the 
relevance of a fine tuning of the single drug concentration 
to obtain the best synergistic effect. Single inhibition of 
Akt was lower when compared with every dual inhibition, 
which in turn was lower than the triple one.
We also demonstrated the importance of two issues: 
the compound concentration and the timing of drugs 
administration. About the first one, two of the drugs, MK-2206 
and GSK690693 were very efficient acting synergistically 
even at low doses, whereas Perifosine administered together 
did not add its efficacy in the 10–20 μM range. The second 
issue disclosed that MK-2206 and GSK690693 may act very 
rapidly (minutes), but Perifosine requires a longer period of 
time (hours), to enter in action and to really synergize with 
MK-2206 and GSK690693.
Figure 5: Triple Akt inhibition induces enhanced autophagy. A The effect of the three drugs administered alone or in combination 
on autophagy, after 24 h of treatment, in MOLT-4, JURKAT and CEM-S cell lines, documented by the lipidation of the autophagy marker 
LC3A/B. The increase in the triple treatment is well evident. Antibody to β-actin served as a loading control. B MTT assays documenting 
the effects of Bafilomycin A1 and Chloroquine on viability of MOLT-4 and CEM-S cells treated for 24 h with Perifosine, GSK690693 and 
MK-2206 administered in combination. Results are mean of three different experiments ± SD. Asterisks indicate significant differences  
(*p < 0.05). One representative experiment of three is shown as well as cell lines are representative also of the others not shown.
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These findings indicate that Akt inhibition mechanism 
may be compatible with a fine tuning of the concentrations 
of the single drugs, that may help with low doses to reduce 
the side effect of the therapy, and with crucial time points in 
which administer the drugs, that otherwise may improve the 
efficacy of the therapy. These needs are present in several 
reports already cited in the introduction [15–17, 20–22]. 
Further studies can sort out this issue.
We also documented the increasing of cleaved PARP 
and caspase-3, well known markers of apoptosis, thus 
showing this as a mechanism for the cytotoxicity of anti 
Akt drugs.
Both autophagy and apoptosis are well-known 
biological processes for programmed cell death, that 
play essential roles in development, tissue homeostasis 
and disease, with interactions among components of the 
Figure 6: Combined Akt inhibition increases apoptosis. A Western blot analysis documenting the increase of PARP or of caspase-3 
cleavage in MOLT-4, JURKAT and CEM-S cell lines, after 24 h of multiple drugs administration when compared with single exposure. 
Antibody to β-actin served as a loading control. B Flow cytometric analysis of MOLT-4, JURKAT and CEM-S cell lines treated with 
Perifosine, GSK690693 and MK-2206 administered alone and in combination for 24 h is reported. Triple drug exposure was also performed 
in the presence of 50 μM Z-VAD-fmk, a pan-caspase inhibitor. In the table are reported the percentages of annexin V positive cells after 
each treatment. Samples were incubated with Annexin V-fluorescein isothiocyanate. Results are the mean of three different experiments ± 
SD. Asterisks indicate statistically significant differences (*p < 0.05). One representative experiment of three is shown as well as cell lines 
are representative also of the others not shown.
Figure 7: Multiple anti Akt drug treatment affects also MEK/ERK pathway. Western blot analysis for Tyr 202/204 p-ERK 
1/2 phosphorylation status in MOLT-4, JURKAT and CEM-S cells, after 24 h of treatment with the three drugs alone and in combination. 
The triple treatment almost abolished p-ERK staining. Twenty-five μg of protein was blotted to each lane. β-actin served as a loading 
control. One representative experiment of three is shown as well as cell lines are representative also of the others not shown.
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two pathways [47]. Autophagy is a cellular catabolic 
degradation process that results in the autophagosomic-
lysosomal degradation of cytosolic proteins and other 
cellular components [48].
Interestingly, here we demonstrated the increment 
of autophagy in multiple anti Akt drugs treated samples. 
Moreover, either the Bafilomycin A1 or the Chloroquine 
autophagy inhibitors, sensitized cells to treatment. These 
findings demonstrated that autophagy is a prosurvival 
mechanism that protected cells from Akt inhibitors 
induced cytotoxicity and the use of autophagy inhibitors 
may be considered in future drug combinations, also in 
clinical trials.
Compensatory upregulation of parallel signaling 
through the MEK/ERK1/2 pathway in response to 
PI3K/Akt inhibition, is an emerging theme in cancer 
cell signal transduction, because it potentially mediates 
resistance to drug-induced growth inhibition [37]. Indeed, 
several recent reports have highlighted the importance 
of functional crosstalks between the MEK/ERK1/2 and 
PI3K/Akt signaling networks, in response to individual 
pathway inhibitors [37, 49–53].
The MEK/ERK1/2 pathway often reflects the 
rebound of Akt inhibition, developing or amplifying 
hyperactivation. Unexpectedly, our results displayed an 
inhibition of ERK activation in correspondence of multiple 
drugs administration. It is tempting to speculate that the 
multi-Akt inhibition could represent an effective treatment 
to block crosstalk between PI3K/Akt/mTOR and Raf/
MEK/ERK reducing tumor growth and cells proliferation.
Genomic DNA mutational analysis of Akt1 exons 
and adjacent splice sites evidenced a somatic point 
mutation in the Pleckstrin Homology domain (PH) of Akt1 
gene: a lysine substitution for glutamic acid at the amino 
acid 17 (E17K). This genetic alteration was originally 
identified in solid tumors [54, 55]. Cystallography studies 
demonstrated that E17K mutation modified Akt1-PH 
conformation and disrupted ionic interaction with Lys 14 
in the lipid-binding pocket of Akt1 [56]. This mutation 
have effects on sensitivity to targeted pathway inhibitors, 
since it has been recently reported that the Akt1- E17K 
mutant cells maintained higher levels of Akt1 Ser 473 
phosphorylation even with increasing concentrations of 
MK-2206 [57].
Very recently a total of five Akt1 variants such as 
E17K, E17S, E319G, L357P, and P388T were found to 
exert deleterious effects on the protein structure and 
function. Furthermore, the molecular docking study 
indicated the lesser binding affinity of inhibitor with 
the mutant structure than the native type. Moreover, the 
findings strongly indicated that screening for Akt1, E17K, 
E17S, E319G, L357P, and P388T variants may be useful 
for disease molecular diagnosis and also to design the 
potential Akt inhibitors [58].
Therefore it appears of great importance to hit Akt as 
a pivotal molecule in cancer development and progression 
with drugs acting with multiple mode of action, to 
overcome the potential resistance due to mutations in the 
site of action of the single drug.
There is great clinical interest in determining 
whether mutations in the PI3K signaling pathway can 
serve as biomarkers to predict sensitivity to drugs 
targeting the pathway. Thus, the presence of Akt mutations 
or of PI3K/Akt/mTOR hyperactivation should be taken in 
account when establishing a therapeutic regimen for the 
patient. This is an important issue toward the personalized 
medicine, since it is useless to activate a treatment if the 
correspondent pivotal cytotoxic target is absent [59].
In conclusion, our preclinical finding strongly 
demonstrated that a multiple inhibition of Akt could 
represent a new promising therapeutic strategy to 
overcome relapse or resistance in the treatment of T- ALL 
patients with hyperactivated PI3K/Akt/mTOR signaling 
pathway.
MATERIALS AND METHODS
Materials
RPMI-1640 medium, fetal bovin serum (FBS), 
penicillin and streptomycin were from Lonza (Lonza 
Milano SRL, Milan, Italy). Perifosine, GSK690693, and 
MK-2206 were from Selleck Chemicals (Houston, TX, 
USA). For cell viability determination, Cell Proliferation 
Kit I (MTT) was purchased from Roche Applied Science 
(Basel, Switzerland). Annexin V/7-AAD detection kit 
was from Merck-Millipore (Darmstadt, Germany). Akt-1, 
Ser 473 p-Akt-1, Tyr 202/204 p-ERK 1/2 and ERK 1/2 
primary antibodies were from Santa Cruz Biotechnology 
(Santa Cruz, CA, USA) while all the other antibodies 
were from Cell Signaling Technology (Danvers, MA, 
USA), including the rabbit secondary antibody. The 
mouse secondary antibody, Bafilomycin A1, Chloroquine 
and Z-VAD-fmk were from Sigma Aldrich (Milan, 
Italy). Signals were detected with the ECL Plus reagent 
purchased from Perkin Elmer (Boston, MA, USA).
Cell culture and Western blot analysis
The T-ALL cell lines were obtained from Deutsche 
Sammlung von Mikroorganismen und Zellkulturen GmbH 
(Braunschweig, Germany). JURKAT, MOLT-4, CEM-S 
(drug sensitive) and CEM-R (CEMVBL100, drug-resistant 
cells overexpressing 170-kDa P-glycoprotein)were grown 
in RPMI 1640 medium supplemented with 10% heat-
inactivated fetal bovine serum (FBS); PEER and BE-13 
were grown in RPMI 1640 with 20% FBS. All the media 
were supplemented with 100 units/ml penicillin and 100 
mg/ml streptomycin. The cells were grown at a density of 
0.5 to 2 × 106 cells/ml and were incubated at 37°C with 
5% CO2. Western Blot analysis was performed by standard 
methods as described elsewhere [60].
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Cell viability analysis
MTT (3-(4,5-dimethylthythiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide) assays were performed as previously 
described [61].
Cell cycle analysis
Cell cycle analysis was performed using propidium 
iodide (PI)/RNase A staining by flow cytometry according 
to standard techniques, as described elsewhere [62]. In 
brief, after 24 h of drug treatment, cells were harvested, 
centrifuged at 300 × g for 5 min and washed once 
with 1X PBS. After fixing them with 70% ethanol at 
20°C, cells were centrifuged at 300 × g for 5 min and 
washed once with 1X PBS. Then 100 μl of propidium 
iodide (PI)/RNase A staining was added to each tube 
with an incubation of 30 min at room temperature in 
the dark. Samples were then analyzed according to the 
manufacturer’s instructions.
PI/Annexin V assay
To determine the extent of apoptosis induction, 
flow cytometric analysis of Annexin V-FITC/PI-stained 
samples was performed [20]. Samples were analyzed on 
an FC500 flow cytometer (Beckman Coulter) with the 
appropriate software (CXP, Beckman Coulter) [60].
Combined drug effect analysis
The combination effect and the potential synergy 
of Perifosine, MK-2206 and GSK690693 were evaluated 
from quantitative analysis of dose–effect relationship, as 
described previously [63].
For each combination experiment, a combination 
index (CI) number was calculated using the 
BiosoftCalcuSyn software (Biosoft, Cambridge, UK). This 
method of analysis generally defines CI values from 0.9 to 
1.1 as additive, from 0.3 to 0.9 as synergistic and below 
0.3 as strongly synergistic, whereas values over 1.1 are 
considered as antagonistic.
Statistical evaluation
The data are presented as mean values from three 
separate experiments ± SD. Data were statistically 
analyzed by a Dunnet test after one-way analysis of 
variance (ANOVA) at a level of significance of p < 0.05 
vs control samples [64].
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